About
Paul L. Feldman has served as Aktis Oncology's Chief Scientific Officer since December 2020. He was previously co-founder and Chief Executive Officer of Phoundry Pharmaceuticals before its acquisition by Intarcia Therapeutics, where he then led discovery and translational medicine, and earlier spent more than 27 years at GlaxoSmithKline where he contributed to the discovery of five approved drugs. He holds a PhD in Chemistry from the University of California, Berkeley and a BS in Chemistry from Duke University.
Roles
Aktis Oncology, Inc.
Chief Scientific Officer · Current role
December 2020–present
Intarcia Therapeutics, Inc.
Head of Discovery and Translational Medicine · Joined via acquisition of Phoundry Pharmaceuticals
2015 - December 2020
Phoundry Pharmaceuticals, Inc.
Co-Founder and Chief Executive Officer · Acquired by Intarcia Therapeutics
until 2015
GlaxoSmithKline
Drug discovery scientist and leader · Part of the discovery of five approved drugs
more than 27 years
External Roles
Chordoma Foundation
Director
—
Fixed Compensation
FY 2025Salary
$447,200
ComponentAnnual base salary earned in FY2025
All other compensation
$1,200
ComponentAll other compensation
Total compensation
$642,415
Performance Compensation
Data from FY 2025Cash incentive
Nonequity incentive plan compensation
$194,015
Target Opportunity
—
PlanAnnual bonus program
Also at Aktis Oncology, Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.